Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: Utility and pitfalls

Frontiers in Oncology

Volumn 3 JUL, Issue , 2013, Pages

  Hinson, Ashley R P ^a   Jones, Rosanne ^b   S Crose, Lisa E ^a   Belyea, Brian C ^c   Barr, Frederic G ^d   Linardic, Corinne M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Alveolar; Embryonal; Human cell line; Rhabdomyosarcoma; Xenograft

Indexed keywords

ALVEOLAR RHABDOMYOSARCOMA CELL LINE; ARTICLE; CANCER CELL CULTURE; CANCER RESEARCH; EMBRYONAL RHABDOMYOSARCOMA CELL LINE; GENE FUSION; HISTOLOGY; HUMAN; HUMAN CELL; INFORMATION PROCESSING; ISOENZYME ANALYSIS; KARYOTYPING; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PUBLICATION; RHABDOMYOSARCOMA; RHABDOMYOSARCOMA CELL LINE IMPORTER; SCIENTIFIC LITERATURE; SHORT TANDEM REPEAT; TUMOR XENOGRAFT; VALIDATION STUDY;

EID: 84891115439     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00183     Document Type: Article

References (87)

1. Saab R, Spunt SL, Skapek SX. Myogenesis and rhabdomyosarcoma the Jekyll and Hyde of skeletal muscle. Curr Top Dev Biol (2011) 94:197-234. doi:10.1016/B978-0-12-380916-2.00007-3
2. Ognjanovic S, Linabery AM, Charbonneau B, Ross JA. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer (2009) 115(18):4218-26. doi:10.1002/cncr.24465
3. Pappo AS, Anderson JR, Crist WM, Wharam MD, Breitfeld PP, Hawkins D, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol (1999) 17(11):3487-93.
4. Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 14(14):4572-83. doi:10.1158/1078-0432.CCR-07-5090
5. Cook B, O'Sullivan F, Leung J, Morse P, Graham B, Chapman AL. Transformation of human embryo cells with the use of cell-free extracts of a human rhabdomyosarcoma cell line (HUS-2): brief communication. J Natl Cancer Inst (1978) 60(5):979-84.
6. Fernandez JE, Prados J, Melquizo C, Arena N, Malavasi F, Alvarez L, et al. Characterization of a new human embryonal rhabdomyosarcoma cell line, RMS-GR. Jpn J Cancer Res (1998) 89(5):525-32. doi:10.1111/j.1349-7006.1998.tb03293.x
7. Garvin AJ, Stanley WS, Bennett DD, Sullivan JL, Sens DA. The in vitro growth, heterotransplantation, and differentiation of a human rhabdomyosarcoma cell line. Am J Pathol (1986) 125(1):208-17.
8. Kleideiter E, Schwab M, Friedrich U, Koscielniak E, Schafer BW, Klotz U. Telomerase activity in cell lines of pediatric soft tissue sarcomas. Pediatr Res (2003) 54(5):718-23. doi:10.1203/01.PDR.0000086901.29111.2A
9. Madsen WE, Walker MJ, Shaughnessy EA, Brown JM, Das Gupta TK. Characterization of malignant mesenchymal cell line (UISO-RS-3) derived from a human rhabdomyosarcoma and inhibition by pharmacologic doses of estrogen. In vitro Cell Dev Biol (1990) 26(10):971-7. doi:10.1007/BF02624471
10. Ozkaynak MF, Nolta J, Parkman R. In vitro purging of human rhabdomyosarcoma cells using 4-hydroperoxycyclophosphamide. Cancer Res (1990) 50(5):1455-8.
11. Urumov IJ, Manolova Y. Cytogenetic analysis of an embryonal rhabdomyosarcoma cell line. Cancer Genet Cytogenet (1992) 61(2):214-5. doi:10.1016/0165-4608(92)90092-M
12. Motoyama T, Watanabe H, Yamamoto T. Embryonal rhabdomyosarcoma in nude mice and in vitro. Acta Pathol Jpn (1986) 36(10):1495-505.
13. Kaneko S, Kaneko M, Ohkawa H. [Establishment and characterization of a childhood embryonal rhabdomyosarcoma cell line with non-random chromosome alterations]. Hum Cell (1995) 8(1):35-41.
14. Ohi S. Characterization, anticancer drug susceptibility and atRA-induced growth inhibition of a novel cell line (HUMEMS) established from pleural effusion of alveolar rhabdomyosarcoma of breast tissue. Hum Cell (2007) 20(2):39-51. doi:10.1111/j.1749-0774.2007.00029.x
15. Ogose A, Motoyama T, Hotta T, Watanabe H. In vitro differentiation and proliferation in a newly established human rhabdomyosarcoma cell line. Virchows Arch (1995) 426(4):385-91. doi:10.1007/BF00191348
16. Sonobe H, Takeuchi T, Taguchi T, Shimizu K, Furihata M, Ohtsuki Y. A new human pleomorphic rhabdomyosarcoma cell-line, HS-RMS-1, exhibiting MyoD1 and myogenin. Int J Oncol (2000) 17(1):119-25.
17. Takaoka E, Sonobe H, Akimaru K, Sakamoto S, Shuin T, Daibata M, et al. Multiple sites of highly amplified DNA sequences detected by molecular cytogenetic analysis in HS-RMS-2, a new pleomorphic rhabdomyosarcoma cell line. Am J Cancer Res (2012) 2(2):141-52.
18. Sokolowski E, Turina CB, Kikuchi K, Langenau DM, Keller C. Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma. Oncogene (2013). [Epub ahead of print]. doi:10.1038/onc.2013.129
19. DeGiovanni C, Nanni P, Nicoletti G, Ceccarelli C, Scotlandi K, Landuzzi L, et al. Metastatic ability and differentiative properties of a new cell line of human embryonal rhabdomyosarcoma (CCA). Anticancer Res (1989) 9(6):1943-9.
20. Magnani I, Faustinella F, Nanni P, Nicoletti G, Larizza L. Karyotypic characterization of a new human embryonal rhabdomyosarcoma cell line. Cancer Genet Cytogenet (1991) 54(1):83-9. doi:10.1016/0165-4608(91)90034-R
21. Martinelli S, McDowell HP, Vigne SD, Kokai G, Uccini S, Tartaglia M, et al. RAS signaling dysregulation in human embryonal rhabdomyosarcoma. Genes Chromosomes Cancer (2009) 48(11):975-82. doi:10.1002/gcc.20702
22. Cinatl J Jr, Cinatl J, Michaelis M, Kabickova H, Kotchetkov R, Vogel JU, et al. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res (2003) 63(7):1508-14.
23. Morton CL, Potter PM. Rhabdomyosarcoma-specific expression of the herpes simplex virus thymidine kinase gene confers sensitivity to ganciclovir. J Pharmacol Exp Ther (1998) 286(2):1066-73.
24. Kelland LR, Bingle L, Edwards S, Steel GG. High intrinsic radiosensitivity of a newly established and characterised human embryonal rhabdomyosarcoma cell line. Br J Cancer (1989) 59(2):160-4. doi:10.1038/bjc.1989.34
25. Clayton J, Pincott JR, van den Berghe JA, Kemshead JT. Comparative studies between a new human rhabdomyosarcoma cell line, JR-1 and its tumour of origin. Br J Cancer (1986) 54(1):83-90. doi:10.1038/bjc.1986.155
26. Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ, et al. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol (2000) 35(2):96-103. doi:10.1002/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z
27. McAllister RM, Melnyk J, Finkelstein JZ, Adams EC Jr, Gardner MB. Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer (1969) 24(3):520-6. doi:10.1002/1097-0142(196909)24:3<520::AID-CNCR2820240313>3.0.CO;2-M
28. Missiaglia E, Selfe J, Hamdi M, Williamson D, Schaaf G, Fang C, et al. Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer (2009) 48(6):455-67. doi:10.1002/gcc.20655
29. Schaaf G, Hamdi M, Zwijnenburg D, Lakeman A, Geerts D, Versteeg R, et al. Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene. Cancer Res (2010) 70(2):762-71. doi:10.1158/0008-5472.CAN-09-2532
30. Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, et al. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res (1992) 52(8):2243-7.
31. Miyachi M, Kakazu N, Yagyu S, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, et al. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res (2009) 15(12):4077-84. doi:10.1158/1078-0432.CCR-08-2955
32. Houghton JA, Houghton PJ, Green AA. Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice. Cancer Res (1982) 42(2):535-9.
33. Chadalapaka G, Jutooru I, Sreevalsan S, Pathi S, Kim K, Chen C, et al. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors. Int J Cancer (2013) 132(4):795-806. doi:10.1002/ijc.27730
34. Stratton MR, Darling J, Pilkington GJ, Lantos PL, Reeves BR, Cooper CS. Characterization of the human cell line TE671. Carcinogenesis (1989) 10(5):899-905. doi:10.1093/carcin/10.5.899
35. Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer (2011) 56(2):239-49. doi:10.1002/pbc.22801
36. Houghton JA, Houghton PJ, Webber BL. Growth and characterization of childhood rhabdomyosarcomas as xenografts. J Natl Cancer Inst (1982) 68(3):437-43.
37. Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, Cenacchi N, et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res (2007) 67(1):32-40. doi:10.1158/0008-5472.CAN-06-0610
38. Marshall AD, Lagutina I, Grosveld GC. PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis. Cancer Res (2011) 71(24):7471-80. doi:10.1158/0008-5472.CAN-11-0924
39. Douglass EC, Valentine M, Etcubanas E, Parham D, Webber BL, Houghton PJ, et al. A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet (1987) 45(3-4):148-55. doi:10.1159/000132446
40. Thompson J, George EO, Poquette CA, Cheshire PJ, Richmond LB, de Graaf SS, et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res (1999) 5(11):3617-31.
41. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 49(7):928-40. doi:10.1002/pbc.21078
42. Roberts I, Gordon A, Wang R, Pritchard-Jones K, Shipley J, Coleman N. Molecular cytogenetic analysis consistently identifies translocations involving chromosomes 1, 2 and 15 in five embryonal rhabdomyosarcoma cell lines and a PAX-FOXO1A fusion gene negative alveolar rhabdomyosarcoma cell line. Cytogenet Cell Genet (2001) 95(3-4):134-42. doi:10.1159/000059335
43. Decristofaro MF, Betz BL, Wang W, Weissman BE. Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors. Oncogene (1999) 18(52):7559-65. doi:10.1038/sj.onc.1203168
44. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest (2002) 110(7):923-32. doi:10.1172/JCI0215634
45. Ito H, Duxbury M, Benoit E, Farivar RS, Gardner-Thorpe J, Zinner MJ, et al. Fibronectin-induced COX-2 mediates MMP-2 expression and invasiveness of rhabdomyosarcoma. Biochem Biophys Res Commun (2004) 318(2):594-600. doi:10.1016/j.bbrc.2004.04.070
46. Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, Marchetti A, et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res (2012) 18(3):748-57. doi:10.1158/1078-0432.CCR-11-2056
47. Kubo K, Naoe T, Utsumi KR, Ishiguro Y, Ueda K, Shiku H, et al. Cytogenetic and cellular characteristics of a human embryonal rhabdomyosarcoma cell line, RMS-YM. Br J Cancer (1991) 63(6):879-84. doi:10.1038/bjc.1991.193
48. Scholl FA, Betts DR, Niggli FK, Schafer BW. Molecular features of a human rhabdomyosarcoma cell line with spontaneous metastatic progression. Br J Cancer (2000) 82(6):1239-45.
49. Mitani K, Kurosawa H, Suzuki A, Hayashi Y, Hanada R, Yamamoto K, et al. Amplification of N-myc in a rhabdomyosarcoma. Jpn J Cancer Res (1986) 77(11):1062-5.
50. Hayashi Y, Sugimoto T, Horii Y, Hosoi H, Inazawa J, Kemshead JT, et al. Characterization of an embryonal rhabdomyosarcoma cell line showing amplification and over-expression of the N-myc oncogene. Int J Cancer (1990) 45(4):705-11. doi:10.1002/ijc.2910450423
51. Whang-Peng J, Knutsen T, Theil K, Horowitz ME, Triche T. Cytogenetic studies in subgroups of rhabdomyosarcoma. Genes Chromosomes Cancer (1992) 5(4):299-310. doi:10.1002/gcc.2870050405
52. Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet (1993) 3(2):113-7. doi:10.1038/ng0293-113
53. Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S, et al. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther (2009) 8(11):3024-35. doi:10.1158/1535-7163.MCT-09-0365
54. Barr FG, Nauta LE, Davis RJ, Schafer BW, Nycum LM, Biegel JA. In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Hum Mol Genet (1996) 5(1):15-21. doi:10.1093/hmg/5.1.15
55. Engel R, Ritterbach J, Schwabe D, Lampert F. Chromosome translocation (2;13)(q37;q14) in a disseminated alveolar rhabdomyosarcoma. Eur J Pediatr (1988) 148(1):69-71. doi:10.1007/BF00441819
56. Taniguchi E, Nishijo K, McCleish AT, Michalek JE, Grayson MH, Infante AJ, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene (2008) 27(51):6550-60. doi:10.1038/onc.2008.255
57. Hazelton BJ, Houghton JA, Parham DM, Douglass EC, Torrance PM, Holt H, et al. Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res (1987) 47(16):4501-7.
58. Houghton JA, Cook RL, Lutz PJ, Houghton PJ. Childhood rhabdomyosarcoma xenografts: responses to DNA-interacting agents and agents used in current clinical therapy. Eur J Cancer Clin Oncol (1984) 20(7):955-60. doi:10.1016/0277-5379(84)90170-6
59. Linardic CM, Naini S, Herndon JE, Kesserwan C, Qualman SJ, Counter CM. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res (2007) 67(14):6691-9. doi:10.1158/0008-5472.CAN-06-3210
60. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ III, Emanuel BS, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet (1993) 5(3):230-5. doi:10.1038/ng1193-230
61. Horton JK, Houghton PJ, Houghton JA. Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard. Cancer Res (1987) 47(23):6288-93.
62. Fiddler TA, Smith L, Tapscott SJ, Thayer MJ. Amplification of MDM2 inhibits MyoD-mediated myogenesis. Mol Cell Biol (1996) 16(9):5048-57.
63. Shapiro DN, Houghton PJ, Hazelton BJ, Germain GS, Murti KG, Rahman A, et al. Morphological and molecular characterization of spontaneous myogenic differentiation in a human rhabdomyosarcoma cell line. Cancer Res (1990) 50(18):6002-9.
64. Barr FG, Nauta LE, Hollows JC. Structural analysis of PAX3 genomic rearrangements in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet (1998) 102(1):32-9. doi:10.1016/S0165-4608(97)00287-2
65. Rodriguez-Perales S, Martinez-Ramirez A, de Andres SA, Valle L, Urioste M, Benitez J, et al. Molecular cytogenetic characterization of rhabdomyosarcoma cell lines. Cancer Genet Cytogenet (2004) 148(1):35-43. doi:10.1016/S0165-4608(03)00216-4
66. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res (1993) 53(22):5535-41.
67. Weber-Hall S, Anderson J, McManus A, Abe S, Nojima T, Pinkerton R, et al. Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res (1996) 56(14):3220-4.
68. Berner JM, Forus A, Elkahloun A, Meltzer PS, Fodstad O, Myklebost O. Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas. Genes Chromosomes Cancer (1996) 17(4):254-9. doi:10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2
69. Khan J, Simon R, Bittner M, Chen Y, Leighton SB, Pohida T, et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res (1998) 58(22):5009-13.
70. Rodeberg DA, Erskine C, Celis E. In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma. J Pediatr Surg (2007) 42(8):1396-402. doi:10.1016/j.jpedsurg.2007.03.041
71. Missiaglia E, Shepherd CJ, Patel S, Thway K, Pierron G, Pritchard-Jones K, et al. MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas. Br J Cancer (2010) 102(12):1769-77. doi:10.1038/sj.bjc.6605684
72. Frascella E, Lenzini E, Schafer BW, Brecevic L, Dorigo E, Toffolatti L, et al. Concomitant amplification and expression of PAX7-FKHR and MYCN in a human rhabdomyosarcoma cell line carrying a cryptic t(1;13)(p36;q14). Cancer Genet Cytogenet (2000) 121(2):139-45. doi:10.1016/S0165-4608(00)00258-2
73. Nanni P, Schiaffino S, De Giovanni C, Nicoletti G, Prodi G, Del Re B, et al. RMZ: a new cell line from a human alveolar rhabdomyosarcoma. In vitro expression of embryonic myosin. Br J Cancer (1986) 54(6):1009-14. doi:10.1038/bjc.1986.273
74. Nicoletti G, De Giovanni C, Landuzzi L, Simone G, Rocchi P, Nanni P, et al. Induction of myogenic differentiation in human rhabdomyosarcoma cells by ionising radiation, N,N-dimethylformamide and their combination. Br J Cancer (1992) 65(4):519-22. doi:10.1038/bjc.1992.107
75. Dias P, Parham DM, Shapiro DN, Tapscott SJ, Houghton PJ. Monoclonal antibodies to the myogenic regulatory protein MyoD1: epitope mapping and diagnostic utility. Cancer Res (1992) 52(23):6431-9.
76. Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene (2002) 21(34):5193-203. doi:10.1038/sj.onc.1205706
77. Martinez-Ramirez A, Rodriguez-Perales S, Melendez B, Martinez-Delgado B, Urioste M, Cigudosa JC, et al. Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques. Cancer Genet Cytogenet (2003) 141(2):138-42. doi:10.1016/S0165-4608(02)00670-2
78. Smith MA, Morton CL, Phelps D, Girtman K, Neale G, Houghton PJ. SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer (2008) 50(3):703-6. doi:10.1002/pbc.21099
79. Walter D, Satheesha S, Albrecht P, Bornhauser BC, D'Alessandro V, Oesch SM, et al. CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS ONE (2011) 6(5):e19506. doi:10.1371/journal.pone.0019506
80. Monsma DJ, Monks NR, Cherba DM, Dylewski D, Eugster E, Jahn H, et al. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med (2012) 10:125. doi:10.1186/1479-5876-10-125
81. Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, et al. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res (2012) 18(14):3780-90. doi:10.1158/1078-0432.CCR-10-3063
82. Drexler HG, Dirks WG, Matsuo Y, MacLeod RA. False leukemia-lymphoma cell lines: an update on over 500 cell lines. Leukemia (2003) 17(2):416-26. doi:10.1038/sj.leu.2402799
83. Dirks WG, Drexler HG. Authentication of cancer cell lines by DNA fingerprinting. Methods Mol Med (2004) 88:43-55.
84. Parson W, Kirchebner R, Muhlmann R, Renner K, Kofler A, Schmidt S, et al. Cancer cell line identification by short tandem repeat profiling: power and limitations. FASEB J (2005) 19(3):434-6.
85. Chen TR, Dorotinsky C, Macy M, Hay R. Cell identity resolved. Nature (1989) 340(6229):106. doi:10.1038/340106b0
86. Boonstra JJ, van Marion R, Beer DG, Lin L, Chaves P, Ribeiro C, et al. Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst (2010) 102(4):271-4. doi:10.1093/jnci/djp499
87. Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A (2001) 98(14):8012-7. doi:10.1073/pnas.121616198